Therapeutic Research

Abstract

Clinical usefulness of dulaglutide was evaluated in 15 type 2 diabetic（T2DM）patients treated with hemodialysis. Dulaglutide was well tolerated in those patients, except the reduction of appetite in some patients（20％）. Dulaglutide improved glycoalbumin by 2.9％ for 3 months in GLP‒1 receptor agonist‒naïve patients, and succeeded in the reduction of insulin dosage in the patients previously treated with insulin. Dulaglutide did not affect body weight before the start of hemodialysis, but significantly reduced body weight gain from last hemodialysis to the next time in GLP‒1 receptor agonist‒naïve patients. Dulaglutide did not affect systolic and diastolic blood pressure before the start of hemodialysis, but significantly increased pulse rates only in GLP‒1 receptor agonist‒naïve patients. The data obtained herein indicated that dulaglutide should be beneficial to glycaemic control of T2DM patients treated with hemodialysis.